Drug intelligence / Profile preview

TBC-M4

Development stage: Phase 1
Lead developer: Therion Biologics
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TBC-M4 is a recombinant modified vaccinia Ankara (MVA) vaccine candidate for HIV prevention. It contains HIV-1 subtype C genes including env, gag, reverse transcriptase (RT), rev, tat, and nef. The vaccine functions as an immunostimulant designed to induce both cellular and humoral immune responses against HIV-1.

Targets

Human immunodeficiency virus type 1 clade C antigens

Beyond the preview

Go deeper on TBC-M4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBC-M4.

Explore the full profile